8-K: Bakhu Holdings Corp. Restructuring and Funding Agreements

Bakhu Holdings Corp. announces new funding and governance agreements with Phytocyte Pty Ltd. and Inter-M Traders FZ-LLE to restore regulatory compliance.

Summary

• Bakhu Holdings Corp. has entered into significant agreements to address its financial and reporting deficiencies.
• A Memorandum of Understanding (MOU) was initially signed on March 17, 2026, with Phytocyte Pty Ltd. and Inter-M Traders FZ-LLE, outlining funding and corporate governance changes.
• Phytocyte agreed to provide up to $600,000 via an interest-free convertible promissory note to cover creditors, vendors, service providers, delinquent SEC filings, and taxes.
• This MOU was terminated on April 17, 2026, due to insufficient funding terms following an SEC inquiry.
• A subsequent Binding Heads of Agreement was entered into on April 7, 2026, with Phytocyte Pty Ltd. for up to $250,000 in funding.
• This new agreement aims to restore the company to good standing, regularize filings, and implement a change of control.
• Phytocyte's funding will be used for SEC compliance, accounting, tax, legal, and corporate restoration expenses.
• Upon satisfaction of a Compliance Restoration Milestone, Phytocyte's funding will convert into 70% of Bakhu's outstanding common stock.
• The company has also appointed new directors and officers, including Konstantia (Nadia) Galazi as President, CEO, Secretary, and CFO, and Karl E. Watkin as a director.
• Qi CPA LLC has been engaged as the new registered public accounting firm.
• The company received an inquiry from the SEC on March 24, 2026, regarding its non-compliance and failure to file mandatory reports, to which it responded with an intent to become current.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautiously optimistic situation. While significant challenges and past failures exist, the new agreements and management provide a potential path to recovery, though substantial risks remain.

Positives

• Secured new funding agreements with Phytocyte Pty Ltd. to address critical financial and compliance needs.
• Agreements are in place to restore the company to regulatory good standing and file delinquent reports.
• New management and board members with relevant experience have been appointed.
• Engaged a new accounting firm to audit financial statements.
• The company is actively working to resolve SEC reporting deficiencies.

Negatives

• The company has a history of delinquent mandatory period reports with the SEC.
• Previous funding agreements (MOU dated March 17, 2026) were terminated due to insufficient funding terms.
• The company received an inquiry from the SEC regarding its non-compliance.
• Significant dilution is expected for existing shareholders upon conversion of Phytocyte's note.
• The company experienced a complete resignation of its previous officers and directors in January 2025 due to deadlock.

Risks

• Failure to satisfy the Compliance Restoration Milestone could prevent the conversion of Phytocyte's note and further funding.
• The SEC could commence administrative proceedings to revoke the company's registration or suspend trading.
• Potential for further delays in filing delinquent reports.
• The company's ability to attract future investment may be impacted by its past compliance issues.
• Interference from Demetri Michalakis, his family, or Inter-M nominees could lead Phytocyte to withdraw from the agreement.

Future Outlook

The company is focused on restoring its regulatory compliance and good standing through new funding and governance arrangements. The success of these efforts is contingent on meeting the Compliance Restoration Milestone, after which Phytocyte will hold a 70% ownership stake. Future financing plans will require board approval.

Management Comments

• The company does not represent, guarantee, or warrant an economic gain or profit with regard to its business, nor the advisability of investing in its stock.
• Any projections, forecasts, or other forward-looking statements or opinions constitute estimates based upon sources deemed reliable, but accuracy is not guaranteed.
• Konstantia (Nadia) Galazi brings significant experience in financial oversight, regulatory remediation, and governance implementation, well-positioned to support companies in achieving and maintaining compliance.
• Karl E. Watkin is described as an entrepreneur, director, salesman, strategist, and inspirational leader with a proven track record of identifying and developing emerging technologies.

Industry Context

StockSavvy.ai notes that Bakhu Holdings Corp. is navigating a critical period of financial restructuring and regulatory remediation, a common challenge for companies with reporting deficiencies. The agreements with Phytocyte Pty Ltd. and Inter-M Traders FZ-LLE highlight the importance of strategic partnerships and capital infusion for survival and revival in the public markets.

Management Changes

Corporate Governance

Legal Proceedings

• The company received an inquiry from the SEC on March 24, 2026, regarding its non-compliance and failure to file mandatory period reports.
• The company requested the SEC refrain from commencing administrative proceedings to revoke its registration or suspend trading, seeking time to become current.

Related Party Transactions

• Inter-M Traders FZ, LLE owns 38.44% of Bakhu's common stock; Demetri Michalakis is director and manager of Inter-M and deemed beneficial owner.
• Demetri Michalakis is the father of Aristotle Popolizio, a former director and executive officer of Bakhu.
• Mentone Ltd., owned by Dr. Peter Whitton, Geoffrey Dixon, and Karl E. Watkin, owns 30% of Cell Science, which licensed technology to Bakhu.
• Karl E. Watkin, a current director, owns and controls Phytocyte Pty Ltd., which is a party to the funding and control agreements.
• John R. Munoz is the beneficial owner of approximately 9,249,161 shares and owner of OZ Company, which provides working capital debt financing and advisory services.
• Efstathios Galazis (former director) is the son of Konstantia (Nadia) Galazi (current director, CEO, etc.).
• Konstantia (Nadia) Galazi is the mother of Efstathios Galazis (former director).

Stakeholder Impact

• Existing shareholders will experience significant dilution upon the conversion of Phytocyte's note, reducing their ownership to 30% on a fully diluted basis.
• Creditors and vendors are expected to be paid through the new funding, resolving outstanding obligations.
• Employees may see improved stability and operational continuity with the new funding and management.
• The SEC and regulatory bodies will see efforts to restore compliance, potentially avoiding further enforcement actions.

Next Steps

• Satisfy the Compliance Restoration Milestone as defined in the Binding Heads of Agreement.
• Prepare and file all overdue SEC mandatory period reports.
• Pay auditors' fees, tax liabilities, filing charges, and compliance costs.
• Complete corporate actions related to the agreement.
• Phytocyte's convertible note will convert into 70% of the company's common stock upon satisfaction of the milestone.
• Update corporate records and governance structures.
• Qi CPA LLC will report on financial statements for the years ending July 31, 2024, and July 31, 2025.

Key Dates

Recommendation

The company is in a critical restructuring phase with new funding and management aimed at restoring compliance. While positive steps are being taken, the significant dilution for existing shareholders, past compliance issues, and the contingent nature of the funding and control transfer warrant a 'hold' recommendation. Investors should await evidence of successful filing and operational stabilization before considering a stronger position.

Keywords

Bakhu Holdings Corp, SEC filings, Form 8-K, Phytocyte Pty Ltd, Inter-M Traders FZ-LLE, Memorandum of Understanding, Binding Heads of Agreement, Convertible Promissory Note, Compliance Restoration, Change of Control, Corporate Governance, Funding, Delinquent Filings, Regulatory Compliance, Qi CPA LLC, Nevada Corporation